AstraZeneca Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	10,225	7,035	5,955	3,288	112
Depreciation & Amortization	5,392	4,981	4,851	5,178	4,039
Other Amortization	236	200	280	292	311
Loss (Gain) From Sale of Assets	-155	-60	-292	-216	-509
Asset Writedown & Restructuring Costs	243	1,623	456	226	2,428
Loss (Gain) From Sale of Investments	-	-	-	-	-776
Loss (Gain) on Equity Investments	7	28	12	5	64
Stock-Based Compensation	366	42	-71	27	45
Other Operating Activities	-602	-1,095	-1,146	-2,749	-1,772
Change in Accounts Receivable	-1,728	-1,624	-1,425	-1,349	-961
Change in Inventory	-755	-131	-669	3,941	1,577
Change in Accounts Payable	1,346	862	2,394	1,165	1,405
Operating Cash Flow	14,575	11,861	10,345	9,808	5,963
Operating Cash Flow Growth	22.88%	14.65%	5.47%	64.48%	24.25%
Capital Expenditures	-2,810	-1,924	-1,361	-1,091	-1,091
Sale of Property, Plant & Equipment	13	55	132	282	13
Cash Acquisitions	-1,230	-3,782	-1,099	-1,035	-10,117
Sale (Purchase) of Intangibles	-2,959	-2,539	-2,126	-1,033	-522
Investment in Securities	-108	-133	-87	-143	605
Other Investing Activities	286	343	477	60	54
Investing Cash Flow	-6,808	-7,980	-4,064	-2,960	-11,058
Short-Term Debt Issued	364	-	161	74	-
Long-Term Debt Issued	15	6,492	3,816	-	12,929
Total Debt Issued	379	6,492	3,977	74	12,929
Short-Term Debt Repaid	-	-31	-	-	-276
Long-Term Debt Repaid	-2,401	-4,968	-5,210	-1,515	-4,999
Total Debt Repaid	-2,401	-4,999	-5,210	-1,515	-5,275
Net Debt Issued (Repaid)	-2,022	1,493	-1,233	-1,441	7,654
Issuance of Common Stock	40	38	33	29	29
Repurchase of Common Stock	-521	-81	-	-	-
Common Dividends Paid	-4,846	-4,602	-4,487	-4,364	-3,856
Other Financing Activities	-195	-844	-880	-1,047	-178
Financing Cash Flow	-7,544	-3,996	-6,567	-6,823	3,649
Foreign Exchange Rate Adjustments	46	-93	-60	-80	-62
Net Cash Flow	269	-208	-346	-55	-1,508
Free Cash Flow	11,765	9,937	8,984	8,717	4,872
Free Cash Flow Growth	18.40%	10.61%	3.06%	78.92%	26.94%
Free Cash Flow Margin	20.03%	18.38%	19.61%	19.66%	13.02%
Free Cash Flow Per Share	7.53	6.36	5.75	5.59	3.41
Cash Interest Paid	1,316	1,313	1,081	849	721
Cash Income Tax Paid	2,845	2,750	2,366	1,623	1,743
Levered Free Cash Flow	7,865	8,461	9,040	12,485	-1,845
Unlevered Free Cash Flow	8,581	9,222	9,602	12,843	-1,608
Change in Working Capital	-1,137	-893	300	3,757	2,021

Updated Feb 10, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q